Wednesday - January 15, 2025
AstraZeneca: Datopotamab Deruxtecan Granted Priority Review in the US for Patients With Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
January 14, 2025
WILMINGTON, Delaware, Jan. 14 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

Application based on TROPION-Lung05 trial and supported by data from TROPION-Lung01 and TROPION-PanTumor01 trials

Approval would mark the first for AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in lung cancer

* * *

AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for da . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products